Feline Chronic Enteropathy and Low-Grade Alimentary Lymphoma
Feline inflammatory bowel disease (IBD), Lymphoplasmacytic enteritis (LPE), Low-grade intestinal T-cell lymphoma (LGITL), Low-grade alimentary lymphoma (LGAL), Small-cell gastrointestinal lymphoma, Food-responsive enteropathy, Chronic small-bowel disease of cats
Chronic enteropathy means the lining of your cat's intestine has been irritated or inflamed for weeks or months. That causes vomiting, loose stools, weight loss, or changes in appetite that keep coming back. The hard part is that ordinary inflammation and a slow-growing intestinal cancer called low-grade lymphoma look almost identical on bloodwork, X-rays and ultrasound, so the only way to tell them apart is a tissue sample (a biopsy) taken under anesthesia. This is not an emergency in most cats, and both versions are usually treatable for a long time. Cats with the cancer version who respond to treatment have lived well over two years on average, so getting the right answer is worth the effort.
What you might notice
- Vomiting that keeps coming back over weeks or months, sometimes with hair or undigested food
- Loose stools or diarrhoea lasting longer than three weeks, or stools that come and go
- Slow weight loss, even when your cat seems to be eating normally
- A big change in appetite in either direction - suddenly ravenous, or picking at food
- Losing muscle along the back and hips, so the spine and hip bones feel sharper
- Less energy, more sleeping, hiding away, or grooming less than usual
- Rumbling gut sounds, gas, or a belly that looks fuller than it used to
- Itchy skin or over-grooming at the same time as the tummy signs
Standard of care
Rule out the look-alikes first, before any long-term drug
Approved / guideline-backedFull physical exam, CBC, biochemistry, total T4 (hyperthyroidism is common in cats over 10 and mimics this), FeLV/FIV status, faecal parasitology, urinalysis, and serum cobalamin plus folate. Abdominal ultrasound to assess wall layering, wall thickness and the jejunal lymph nodes. Imaging narrows the differential but cannot make the diagnosis.
Named products: No drug at this step.
The 2023 ACVIM consensus statement concludes that 'no single diagnostic criterion or known biomarker reliably differentiates inflammatory lesions from neoplastic lymphoproliferations in the intestinal tract of cats and a diagnosis currently is established by integrating all available clinical and diagnostic data.'
Run a strict elimination diet trial for 2-4 weeks - this is the single highest-yield intervention and it is free of drug risk
Controlled trial in this speciesA commercial hydrolysed or single novel-protein diet, fed exclusively: no treats, no flavoured medications, no other household cat's food. Re-challenge with the previous diet afterwards to confirm. Roughly half of cats with chronic idiopathic GI signs respond to diet alone.
Named products: Diet only. No named drug.
In 55 cats with chronic idiopathic gastrointestinal signs, 16 (29%) were diagnosed food-sensitive on dietary elimination-challenge using commercial selected-protein diets, and a further 11 (20%) resolved on the elimination diet but did not relapse on challenge. Diagnosis could NOT be made from clinical signs, routine clinicopathology, serum antigen-specific IgE, gastroscopic food sensitivity testing, or GI biopsy - only from the trial itself.
Measure and correct cobalamin (vitamin B12)
Controlled trial in this speciesHypocobalaminaemia is common in feline small-bowel disease and contributes to inappetence and weight loss. In a retrospective series of 25 cats with serum cobalamin at or below 250 pmol/L and clinical signs of chronic enteropathy, 0.25 mg cyanocobalamin tablets once daily raised serum cobalamin above the reference interval in ALL 25 cats (median 128 pmol/L before, 2701 pmol/L after; P<0.0001) - so oral dosing is a viable alternative to weekly injections, though the authors call for prospective comparative trials before routine substitution.
Named products: Cyanocobalamin 0.25 mg tablets PO q24h was the regimen studied. No FDA NADA for a feline chronic-enteropathy indication was located.
Retrospective single-centre series, n=25 cats, oral route; 78% of tested cats in a separate 41-cat low-grade lymphoma series had low serum cobalamin, establishing how often this needs checking.
Biopsy before committing to long-term immunosuppression or chemotherapy
Approved / guideline-backedEndoscopic or full-thickness surgical biopsy with histopathology plus immunohistochemistry, and clonality testing where available. Full-thickness biopsy reaches jejunum and ileum that endoscopy cannot, at the cost of a laparotomy. The consensus panel explicitly cautions against reclassifying a cat previously diagnosed with IBD as lymphoma on the basis of clonality testing alone.
Named products: No drug at this step. General anaesthesia is required; there is no non-invasive substitute, and no product PetSmartMeds sells may be positioned as one.
ACVIM consensus 2023: histopathology remains the mainstay for differentiating LPE from LGITL; most panel recommendations rest on a moderate or low level of evidence, and few prospective studies exist. Paulin 2018: 'A combination of conventional histopathology and immunohistochemistry remains the current gold-standard test.'
Inflammatory chronic enteropathy (LPE): prednisolone, tapered to the lowest effective dose - and never prednisone
Controlled trial in this speciesPrednisolone 1-2 mg/kg PO q24h, then tapered according to clinical response, was the standard comparator arm in the only randomised feline chronic-enteropathy trial. Dose on lean or ideal body weight. Prednisone must not be substituted for prednisolone in cats: a single 2 mg/kg oral dose of prednisolone produced roughly 4-fold higher plasma prednisolone AUC than the same dose of prednisone in cats.
Named products: Prednisolone (oral). No FDA NADA or EMA marketing authorisation for a feline chronic-enteropathy indication was located in this research; use for this indication is extralabel under 21 CFR 530.30. Do NOT substitute prednisone.
Prednisolone 1-2 mg/kg q24h tapered to response served as the active comparator in a randomised, owner-blinded trial (n=6 per arm) and produced a mean FCEAI of 3.7 at six months from a pretreatment mean of 3.6. Feline prednisone/prednisolone pharmacokinetics: two-drug crossover in 11 cats, HPLC plasma concentrations, ~4-fold higher AUC for prednisolone.
Low-grade alimentary lymphoma (LGITL/LGAL): chlorambucil plus a glucocorticoid
Controlled trial in this speciesThis is the best-supported protocol in feline oncology for this disease, and the response durations are long. Dosing protocols are not standardised across the literature; the pharmacokinetic study that informs current practice used a 2 mg total oral dose given every other day, which showed rapid absorption, a terminal half-life of 1.8 h, and no accumulation between doses in 24 cats.
Named products: Chlorambucil (human-labelled alkylating agent, marketed as Leukeran) plus prednisolone. No FDA NADA for any feline indication was located in this research; veterinary use is extralabel use of an approved human drug under 21 CFR 530.30. Chlorambucil is cytotoxic - see safety.
28 cats (24 with full-thickness biopsies) with small-cell GI lymphoma treated with chlorambucil plus glucocorticoids: overall clinical response rate 96%, median clinical remission duration 786 days; 7 cats relapsed and all 7 responded to cyclophosphamide rescue. Separately, 41 cats with low-grade lymphocytic lymphoma on prednisone plus chlorambucil: 56% complete response, 39% partial response, 5% no response; median remission 897 days after complete response vs 428 days after partial response; overall median survival 704 days. Both are retrospective, single- or few-centre series with no control arm.
Relapsed LGAL: cyclophosphamide as first rescue
Controlled trial in this speciesFor cats that relapse after chlorambucil, cyclophosphamide is the best-documented first rescue option.
Named products: Cyclophosphamide. Extralabel use of an approved human drug; no FDA NADA for a feline LGAL indication was located.
20 cats across three institutions with clinically presumed relapsed LGAL after failing chlorambucil: 18/20 (90%) achieved a complete clinical response for a median 239 days; median progression-free survival 215 days; median overall survival time 1065 days; adverse events were few and reversible. Retrospective, no control arm.
Nutritional support and appetite management while the primary disease is being controlled
Approved / guideline-backedWeight, body condition score and muscle condition score at every visit. Address inappetence early rather than waiting; assisted feeding is appropriate where a cat will not maintain intake. Cats that stop eating are at risk of hepatic lipidosis.
Named products: No named drug is asserted here. We did not verify an FDA-approved feline appetite stimulant for this indication in this research and will not name one.
ISFM consensus guidelines on the management of the inappetent hospitalised cat cover assisted feeding, feeding tubes and appetite stimulation in this population.
Order of operations - state this plainly to clients
Approved / guideline-backedDiagnosis, diet and correctly dosed conventional drugs outperform every injectable on the evidence available today. No cell product, exosome product or peptide has ever been shown to beat prednisolone or chlorambucil in a cat, and none has been studied at all in cats with low-grade alimentary lymphoma. A biologic may only ever be discussed as an adjunct or as an option for a cat that has failed or cannot tolerate standard therapy, and only inside an informed-consent conversation.
Named products: Not applicable.
The published feline biologic evidence base for this condition totals 13 treated cats across two studies from one research group, neither of which enrolled a cat with lymphoma; the chlorambucil literature covers 69 cats with response rates of 56-96% and remission durations measured in years.
ACVIM consensus statement guidelines on diagnosing and distinguishing low-grade neoplastic from inflammatory lymphocytic chronic enteropathies in cats — American College of Veterinary Internal Medicine (ACVIM)
How it is diagnosed
- History and physical exam focused on duration, weight trajectory, appetite direction (polyphagia is a discriminator), vomiting vs diarrhoea vs both, and concurrent dermatological signs.
- CBC, serum biochemistry, total T4 (to exclude hyperthyroidism, which mimics this in older cats), FeLV/FIV status, urinalysis, and faecal parasitology to exclude the treatable look-alikes.
- Serum cobalamin and folate - hypocobalaminaemia was present in 78% of tested cats in one 41-cat low-grade lymphoma series and both guides treatment and localises disease.
- A strict 2-4 week hydrolysed or novel-protein elimination diet trial with re-challenge, BEFORE immunosuppression. Roughly half of cats with chronic idiopathic GI signs respond to diet, and food sensitivity cannot be diagnosed any other way - not by signs, not by serum IgE, not by biopsy.
- Abdominal ultrasound assessing wall thickness and layering, and specifically the jejunal lymph nodes; a rounded jejunal lymph node and small-volume abdominal effusion tended to favour LGITL over LPE. Imaging narrows, it does not decide.
- Endoscopic or full-thickness surgical biopsy with histopathology plus immunohistochemistry, and clonality testing where available - required before long-term immunosuppression or chemotherapy. Full-thickness biopsy samples jejunum and ileum that endoscopy cannot reach.
- Integrate everything rather than trusting one test: the 2023 ACVIM consensus panel found no single criterion or biomarker that reliably separates LPE from LGITL, and cautioned against reclassifying a previously diagnosed IBD cat as lymphoma on clonality testing alone.
Where a biologic fits
Our own product, graded by the same rule
In two small single-centre studies from one research group - a blinded placebo-controlled proof-of-concept in 7 treated cats and a randomised owner-blinded comparison of 6 cats per arm against prednisolone - two intravenous doses of allogeneic FELINE adipose-derived mesenchymal stromal cells improved clinical signs of chronic enteropathy with no adverse effects attributed to treatment, and at six months the cell-treated cats' mean Feline Chronic Enteropathy Activity Index was 0.75 versus 3.7 for prednisolone; no multicentre or placebo-controlled trial has been published, no cat with low-grade alimentary lymphoma has ever been enrolled, no exosome or peptide product has any published in-vivo efficacy evidence in cats with gastrointestinal disease, and no cell- or exosome-based product is FDA-approved for any use in cats.
What exists
FELINE ADIPOSE-DERIVED MSC, LIVE CELLS, INTRAVENOUS - two small studies, one research group (Colorado State University), both in cats with non-neoplastic chronic enteropathy. (1) Blinded, placebo-controlled proof-of-concept: 7 cats with diarrhoea of at least 3 months' duration received allogeneic adipose-derived feline MSC (fMSC) and 4 received placebo, blinded, with no diet or medication changes during the study; 3 further cats were treated open-label. No adverse reactions or side effects were attributed to fMSC in any cat. Owners of 5/7 fMSC cats reported significant improvement or complete resolution; the other 2 reported modest but persistent improvement; owners of placebo cats reported no change or worsening. The authors state 'these preliminary results require significant follow-up study.' Webb TL, Webb CB. J Feline Med Surg. 2015;17(10):901-8. PMID 25480816. DOI 10.1177/1098612X14561105. (2) Randomised, owner-blinded, active-comparator trial with NO placebo arm: cats that failed a 2-week diet trial and had endoscopic-biopsy-confirmed IBD were randomised to fMSC (two IV injections of 2 x 10^6 freshly cultured allogeneic cells/kg, 14 days apart) or prednisolone 1-2 mg/kg PO q24h tapered to response; 6 per arm completed and one cat in each arm failed at the 2-month recheck. At 6 months mean FCEAI was 3.7 (range 0.5-9) for prednisolone vs 0.75 (range 0-1.5) for fMSC, from near-identical pretreatment means of 3.6 and 3.7. The authors' own conclusion is equivalence, not superiority: 'this specific fMSC protocol appears to be as effective in the treatment of feline IBD as a standard course of prednisolone therapy.' Webb TL, Webb CB. J Feline Med Surg. 2022;24(8):e244-e250. PMID 35713592. DOI 10.1177/1098612X221104053. Known caveats: n=6 per arm, single centre, no placebo, baseline body weight differed between arms (3.6 vs 4.9 kg), and only owners are stated to have been blinded. Context on the whole feline field: a 2024 two-part review of all feline MSC literature found 108 publications of which 26 administered MSC to 215 cats, only 12 studies had a control group, with 7 cell sources, 9 routes, 12 vehicles and a 300-fold dosage range, median 6.5 treated cats per study, and concluded 'current evaluations are mostly still in the discovery phase' and 'no approved stem cell products are available for use in cats in the US' (Webb TL, Webb CB. J Am Vet Med Assoc. 2024, Parts 1 and 2. DOI 10.2460/javma.24.02.0074 and DOI 10.2460/javma.24.02.0080 — article titles were not independently verified in this research and must be confirmed before typesetting a reference list). Everything else in this space is an induced model or a rodent: a DSS-induced feline IBD model treated with MSC (Xie Q, et al. Stem Cell Res Ther. 2024. DOI 10.1186/s13287-024-04038-y) and DSS colitis in MICE treated with feline-derived MSC or their PGE2 (An JH, et al. BMC Vet Res. 2018. DOI 10.1186/s12917-018-1684-9; Kim H, et al. J Vet Sci. 2023. DOI 10.4142/jvs.23106). Induced-model and mouse data are not feline clinical evidence and must never be presented as such.
What has not been shown
1. NO exosome or extracellular-vesicle evidence of any kind in cats with gastrointestinal disease. There is no published in-vivo efficacy study of any exosome or EV preparation in a cat or a dog with chronic enteropathy, IBD, or alimentary lymphoma. The single best-designed in-vivo companion-animal EV trial located anywhere in the literature is a 30-cat randomised active-comparator study in limbal stem cell deficiency - an OCULAR indication with no bearing on the gut (Ergin I, et al. Vet Res Commun. 2025;49(6):349. PMID 41055800. DOI 10.1007/s11259-025-10908-4). 2. NO peptide evidence. Searches for BPC-157, TB-500, KPV, LL-37 and GHK-Cu in cats with chronic enteropathy returned no controlled efficacy study in any companion-animal species. BPC-157 has exactly one genuine veterinary record and it is beagle pharmacokinetics with no efficacy endpoint of any kind: elimination half-life under 30 minutes, intramuscular bioavailability 45-51% in beagle dogs (He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717. DOI 10.3389/fphar.2022.1026182). KPV and BPC-157 have rodent colitis data only; rodent colitis is not feline chronic enteropathy. TB-500 is banned by the FEI. 3. NO biologic evidence in low-grade alimentary lymphoma. Neither feline MSC study enrolled a cat with LGITL or LGAL, and treating a T-cell lymphoproliferative disorder with an immunomodulatory cell product has no evidentiary basis and a coherent theoretical hazard. Biologics must not be offered for the lymphoma arm of this disease. 4. NO xenogeneic evidence in the feline gut. There is no study of equine or human umbilical-cord MSC or their derivatives in cats with GI disease. Carrying the DogStem result across does not work: DogStem (EMA EMEA/V/C/005829) is authorised for canine OSTEOARTHRITIS in DOGS using EQUINE umbilical-cord MSC, and reported 51% of treated dogs vs 5% of placebo meeting a force-plate gait endpoint at 8 weeks - a different species, a different tissue, a different disease. 5. 'IMMUNE-PRIVILEGED' IS NOT A DEFENSIBLE CLAIM and we will not publish it. In a randomised controlled safety trial of 24 young healthy police working dogs given intra-articular xenogeneic equine umbilical-cord MSC, allogeneic canine adipose MSC or placebo 1:1:1, no adverse events were detected after single or repeated administration BUT, in the authors' own words, 'both equine and canine MSC generate antibody titres in the dogs' (Punzon E, Garcia-Castillo M, Rico MA, Padilla L, Pradera A. Local, systemic and immunologic safety comparison between xenogeneic equine umbilical cord mesenchymal stem cells, allogeneic canine adipose mesenchymal stem cells and placebo: a randomized controlled trial. Front Vet Sci. 2023;10:1098029. PMID 37266387. DOI 10.3389/fvets.2023.1098029 — note all but one author are employed by EquiCord S.L., the DogStem manufacturer; disclose this whenever citing it). These products are not immune-invisible, and the finding holds for the allogeneic route as well as the xenogeneic one. 6. NO APPROVED PRODUCT. In the United States no animal cell-, tissue- or exosome-based product is FDA-approved for any species or indication; such products are unapproved new animal drugs. FDA has enforced against conditioned media - the upstream material from which exosome preparations are made - as an unapproved new animal drug, and FDA's 2019 public safety notification states plainly that 'there are currently no FDA-approved exosome products.' Separately, 21 CFR 530.4 prohibits advertising or promoting extralabel uses even of lawfully approved drugs, so 'educational content' that functions as extralabel promotion is extralabel promotion.
Sources
- Feline MSC proof-of-concept in chronic enteropathy, n=7 treated, blinded, placebo-controlled — Webb TL, Webb CB. Stem cell therapy in cats with chronic enteropathy: a proof-of-concept study. J Feline Med Surg. 2015;17(10):901-8. PMID 25480816. DOI 10.1177/1098612X14561105 https://doi.org/10.1177/1098612X14561105
- Feline MSC vs prednisolone in biopsy-confirmed IBD, randomised, n=6 per arm, no placebo — Webb TL, Webb CB. Comparing adipose-derived mesenchymal stem cells with prednisolone for the treatment of feline inflammatory bowel disease. J Feline Med Surg. 2022;24(8):e244-e250. PMID 35713592. DOI 10.1177/1098612X221104053 https://doi.org/10.1177/1098612X221104053
- Both allogeneic AND xenogeneic MSC raised antibody titres in HEALTHY dogs - why 'immune-privileged' is not publishable — Punzon E, Garcia-Castillo M, Rico MA, Padilla L, Pradera A. Local, systemic and immunologic safety comparison between xenogeneic equine umbilical cord mesenchymal stem cells, allogeneic canine adipose mesenchymal stem cells and placebo: a randomized controlled trial. Front Vet Sci. 2023;10:1098029. PMID 37266387. DOI 10.3389/fvets.2023.1098029. n=24 young healthy police working dogs, intra-articular, 1:1:1. No adverse events; 'both equine and canine MSC generate antibody titres in the dogs'. Author conflict: EquiCord S.L. (DogStem manufacturer). https://doi.org/10.3389/fvets.2023.1098029
- Best in-vivo companion-animal exosome trial located - CATS, but an OCULAR indication, not gastrointestinal — Ergin I, Sainkaplan S, Isik M, Cinar OO, Bayraktaroglu AG, Derkus B, Senel OO. Therapeutic effects of adipose mesenchymal stem cell-derived exosomes on limbal stem cells deficiency in cats. Vet Res Commun. 2025;49(6):349. PMID 41055800. DOI 10.1007/s11259-025-10908-4 https://doi.org/10.1007/s11259-025-10908-4
- Only genuine BPC-157 veterinary record - beagle pharmacokinetics, no efficacy endpoint in any species — He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717. DOI 10.3389/fphar.2022.1026182 https://doi.org/10.3389/fphar.2022.1026182
- Two-part review of the entire feline MSC literature - 215 cats, only 12 controlled studies, 300-fold dose range, 'still in the discovery phase' — Webb TL, Webb CB. J Am Vet Med Assoc. 2024, Parts 1 and 2. DOI 10.2460/javma.24.02.0074 and DOI 10.2460/javma.24.02.0080. NOTE: exact article titles were not independently verified in this research - confirm before publishing a reference list. https://doi.org/10.2460/javma.24.02.0074
- FDA: no approved exosome products (human-side notification; the veterinary-side ACTP position is that no animal cell/tissue product is approved) — FDA. Public Safety Notification on Exosome Products, 6 December 2019. https://www.fda.gov/vaccines-blood-biologics/safety-availability
Tracking response
How you know whether it is working
Clinicians track this with Feline Chronic Enteropathy Activity Index (FCEAI).
Jergens AE, Crandell JM, Evans R, Ackermann M, Miles KG, Wang C. A clinical index for disease activity in cats with chronic enteropathy. J Vet Intern Med. 2010;24(5):1027-33. PMID 20584141. DOI 10.1111/j.1939-1676.2010.0549.x. Developed in 82 cats: retrospective review of 59 cats with IBD plus a prospective validation cohort of 23 cats with IBD or food-responsive enteropathy. The index combines gastrointestinal signs, endoscopic abnormalities, serum total protein, ALT/ALP activity and serum phosphorus. It is the outcome measure used in both feline MSC studies and is therefore the instrument any PetSmartMeds follow-up must be benchmarked against.
Published in Journal of Veterinary Internal Medicine (Wiley). No public licence terms, fee schedule or permission requirement were located for the FCEAI in this research - that is an unresolved question, not a confirmed permission, so written clearance from the publisher should be obtained before reproducing the scoring table verbatim on a commercial page. Two hard constraints follow from the instrument itself: the FCEAI contains an ENDOSCOPIC component and laboratory values, so it cannot be scored by an owner at home, and the owner-facing questions below are a plain-language proxy for tracking change between visits - they are NOT the validated FCEAI and must never be labelled as an FCEAI score.
Suggested cadence: Weight, body condition score and muscle condition score at EVERY visit - weight trajectory is the most honest single number in this disease. Recheck 2-4 weeks after any diet change or drug change. On chlorambucil: CBC before starting, then serial CBCs per the immunosuppressant-monitoring literature, with a urine dipstick for glucose at each CBC to screen for chlorambucil-associated Fanconi syndrome (which was clinically silent in 3 of 4 reported cats). Serum cobalamin at diagnosis and again 4-6 weeks after starting supplementation. Full FCEAI scoring only at the timepoints where endoscopy and bloodwork are actually being repeated - typically diagnosis and any decision point about changing therapy. Owner check-in weekly during induction, then monthly once stable. Note that the published feline MSC trials used a 2-month and a 6-month recheck, so any comparison to them needs those same timepoints.
Questions you can answer at home
- How many times did your cat vomit this week? (Count hairballs too.)
- What did the stools look like - firm, soft-but-formed, pudding, or liquid? How many days this week were not normal?
- Is your cat eating more, the same, or less than a month ago - and is it finishing meals?
- What is the weight this week? (A home scale reading to the nearest 100 g is genuinely useful; weight is the number we trust most.)
- Is your cat jumping, playing and grooming as much as usual, or hiding and sleeping more?
- Did you give any treat, table food, flavoured medicine, or another cat's food this week? (Even a small slip can break a diet trial.)
- Any new symptom since the last check-in - straining, blood, refusing food for a whole day, or drinking much more?
Build a profile for your pet
Tell us what you are dealing with and the site will show you only what applies.